April 2017

ProFem announces Start of the Phase II Dose Escalation Study with Candiplus® in Patients with Vulvovaginal Candidiasis (VVC)

The ProF-001_IIa is a phase IIa randomized, active-controlled, double-blind, dose-escalation study in patients with vulvovaginal candidiasis to evaluate efficacy, safety and tolerability of topically administered Candiplus® that will enroll 84 patients in three study centers across Austria. The aim is to evaluate if Candiplus® is superior to standard of care in the combined primary endpoint of symptom relief within the first hour and clinical cure after the active treatment period. Candiplus® is based on a new therapeutic strategy consisting of a combination of two already marketed active ingredients, for the treatment of acute and recurrent VVC addressing a hitherto unaddressed pathogenetic mechanism. 

March 2017

Approval of clinical phase 2a study – dose escalation of Candiplus® by BASG

Phase 2 a study – dose escalation of Candiplus® – approved by BASG.

After approval of our planned phase 2 dose escalation study by BASG recruiting of patients will start in the beginning of April. This study will be conducted at the departments of Obstetrics and Gynecology at the Medical Universities of Vienna and Innsbruck as well as at the BKH Schwaz.

ProFem’s lead product Candiplus targets recurrent vulvovaginal candiosis RVVC, a very frequent and painful disease among women between 18 and 55, which cannot be treated adequately up to now. Candiplus, a patented combination of two drugs in a topical administration reduces pain immediately and cures the disease within 3 to 7 days.

February 2017

ProFem FFG KLIPHA financing granted

In February 2017 FFG  financing was granted based on the KLIPHA program.

“We are very happy that we could win this substantial financing by FFG,” says DDr. Marion Noe, founder and Chief Executive Officer of ProFem. “This supports us substantially to promote our exciting lead project Candiplus® through the clinical program.”

 

December 2015

ProFem AWS seed financing granted

In December 2015 the AWS seed financing was granted in a competitive process by the AWS board.

“We are very happy that we could win this substantial seed financing by the Austrian Economic Agency (AWS),” says DDr. Marion Noe, founder and Chief Medical Officer of ProFem. “This allows us to substantially push our exciting lead project Candiplus, prepare our clinical program and get approval from the authorities and the ethic commission.”

ProFem’s lead product Candiplus targets recurrent vulvovaginal candioses RVVC, a very popular and painful disease among women between 18 and 55, which cannot be treated adequately up to now. Candiplus, a patented combination of two drugs in a topical administration reduces pain immediately and cures the disease within 3 to 7 days.